Exon 19 deletions and the L858R substitution in exon 21 are the most frequent epidermal growth factor receptor (EGFR)-activating mutations in non-small-cell lung cancer (NSCLC) and are associated with the sensitivity to EGFR tyrosine kinase inhibitors (TKIs), including the first-generation (1st-gen) gefitinib and erlotinib, second-generation (2nd-gen) afatinib and dacomitinib, and third-generation (3rd-gen) osimertinib (Mok et al., 2009; Soria et al., 2018). This evidence concerns the gene EGFR and non-small cell lung carcinoma.